Current through Register Vol.. 38, No. 17, April 11, 2022
Physicians and directors of medical care
facilities are required to submit all of the following:
1. An initial report to be completed when
there are reasonable grounds to suspect that a person has active TB disease,
but no later than when antituberculosis drug therapy is initiated. The reports
must include the following: the affected person's name; age; date of birth;
gender; address; pertinent clinical, radiographic, microbiologic and pathologic
reports, whether pending or final; such other information as may be needed to
locate the patient for follow-up; and name, address, and telephone number of
the treating physician.
secondary report to be completed simultaneously or within one to two weeks
following the initial report. The report must include:
(i) the date, method, and results of tests
for tuberculosis infection;
the date and results of the initial and any follow-up chest
(iii) the dates and
results of bacteriologic or pathologic testing, the antituberculosis drug
regimen, including names of the drugs, dosages and frequencies of
administration, and start date;
(iv) the date and results of drug
(vi) contact screening
address, and telephone number of treating physician.
3. Subsequent reports are to be made when
updated information is available. Subsequent reports are required when clinical
status changes, the treatment regimen changes; treatment ceases for any reason;
or there are any updates to laboratory results, treatment adherence, name,
address, and telephone number of current provider, patient location or contact
information, or other additional clinical information.
4. Physicians or directors of medical care
facilities responsible for the care of a patient with active tuberculosis
disease are required to develop and maintain a written treatment plan. This
plan must be in place no later than the time when antituberculosis drug therapy
is initiated. Patient adherence to this treatment plan must be documented. The
treatment plan and adherence record are subject to review by the local health
director or his designee at any time during the course of treatment.
The treatment plan for the following
categories of patients must be submitted to the local health director or his
designee for approval no later than the time when antituberculosis drug therapy
is started or modified:
a. For individuals who
are inpatients or incarcerated, the responsible provider or facility must
submit the treatment plan for approval prior to discharge or
inpatient, incarcerated, or outpatient, who also have one of the following
(1) HIV infection.
(2) Known or suspected active TB disease
resistant to rifampin, rifabutin, rifapentine or other rifamycin with or
without resistance to any other drug.
(3) A history of prior treated or untreated
active TB disease, or a history of relapsed active TB disease.
(4) A demonstrated history of nonadherence to
any medical treatment regimen.
Laboratories are required to submit the
1. Results of smears that are
positive for acid fast bacilli.
Results of cultures positive for any member of the Mycobacterium tuberculosis
complex or any other mycobacteria.
3. Results of rapid methodologies, including
acid hybridization or nucleic acid amplification, which are indicative of M.
tuberculosis complex or any other mycobacteria.
4. Results of tests for antimicrobial
susceptibility performed on cultures positive for M. tuberculosis
5. Results of tests for
Laboratories, whether testing is done in-house or referred to an out-of-state
laboratory, shall submit a representative and viable sample of the initial
culture positive for any member of the M. tuberculosis complex to the Virginia
Division of Consolidated Laboratory Services or other laboratory designated by
the board to receive such specimen.
Admin. Code §
Derived from Virginia
Register Volume 20, Issue 21, eff. July 28, 2004; amended, Virginia Register
Volume 23, Issue 15, eff. May 2, 2007; Volume 27, Issue 13, eff. March 28,
Register Volume 36, Issue 06, eff.
Statutory Authority: §§
of the Code of Virginia.